NPS Pharmaceuticals (NASDAQ: [[ticker:NPSP]]) of Bedminster, NJ, announced that its Swiss-based development partner Nycomed has filed for European clearance to market teduglutide (Revestive) for the treatment of short bowel syndrome. The submission triggers a milestone payment to NPS that the company says is in the mid-seven digits. NPS expects to file for approval to market teduglutide in the U.S. later this year, and it has licensed Nycomed the rights to commercialize the drug beyond North America. The drug, a novel analog of a human peptide that helps maintain normal intestinal function, could bring in sales of $350 million a year in the U.S., NPS has estimated.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
